Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety study
- 7 May 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 41 (9) , 1445-1451
- https://doi.org/10.1016/s0735-1097(03)00255-9
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summaryJournal of the American College of Cardiology, 2001
- SPAF-III resultsEuropean Heart Journal, 1996
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1992
- Canadian atrial fibrillation anticoaguiation (CAFA) studyJournal of the American College of Cardiology, 1991
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Stroke Prevention in Atrial Fibrillation Study. Final results.Circulation, 1991
- The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1990
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988
- The Barthel ADL Index: A reliability studyInternational Disability Studies, 1988